garajstock / Shutterstock.com
8 August 2016Americas
AstraZeneca sues Mylan after Faslodex generic bid
AstraZeneca has sued Mylan for allegedly infringing its patents covering the drug Faslodex (fulvestrant).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Editor's picks
Editor's picks
Americas
9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.